GRANTOR STATEMENT
This Educational Activity was made possible in part by a grant from Bausch + Lomb.

Learning Objectives

Upon completion of this activity, participants will be better able to:
•Explain how novel therapeutics differ in their methods of action from other topical medications.
•Evaluate the safety and efficacy of latanoprostene bunod for ocular hypertension and primary open-angle glaucoma.
•Describe how a healthy eye manages intraocular pressure in contrast with an unhealthy eye.

Accreditation and Designation Statement

Accreditation Statement
Evolve Medical Education LLC (Evolve) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation Statement
Evolve designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

In cooperation with Evolve Medical Education LLC, the University of Houston College of Optometry has reviewed and endorsed this course.

Evolve is an approved COPE Administrator. This course is COPE approved for 1.0 hours of CE Credit for Optometrists.
COPE Course ID: 60201-GL
COPE Event ID: 116630

COPE EXPIRATION DATE: December 10, 2021

Faculty and Disclosures

Nathan Radcliffe, MD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Aerie; Alcon/Novartis; Allergan; Glaukos; Baush + Lomb; Beaver Visitec; Carl Zeiss Meditec; Ellex; Endo Optiks; Equinox; Iridex; Ivantis; Lumenis; New World Medical; Ocular Science; Omeros; Reichert; Sight Science; TearScience; Speaker: Aerie; Alcon/Novartis; Allergan; Alimera; Glaukos; Baush + Lomb; Beaver Visitec; Carl Zeiss Meditec; Equinox; Iridex; Lumenis; New World Medical; Ocular Science; Reichert; Sight Science;

James Thimons, O.D., FAAO., has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Speaker: Aerie; Alcon/Novartis; Allergan; Baush + Lomb; Carl Zeiss Meditec; Diopsys; Glaukos; InFocus; PRN; Reichert; Shire; Tear Lab;

Editorial Support Disclosure

Susan Gallagher-Pecha, director of client services and project management, Evolve Medical Education LLC, and Erin Fletcher, MIT, Evolve Medical Education LLC, have no real or apparent conflicts of interest to report. Jaya Kumar, MD, peer reviewer has no conflict of interest to report.

Disclaimer

Off-Label Statement
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Evolve or Bausch & Lomb.

Forget your password?

Pretest

1. Please rate your confidence on your ability to apply updates in glaucoma treatment in the clinic. (Based on a scale of 1 to 5, with 1 being not at all confident and 5 being extremely confident).*
1 2 3 4 5
2. Please rate how often you apply advanced glaucoma treatment to “real-world” patient management. (Based on a scale of 1 to 5, with 1 being never and 5 being always).*
1 2 3 4 5
3. Prostaglandin analogs (PGAs) remain the standard first-line treatment over selective laser trabeculoplasty (SLT) because ________.*
- a. PGAs are more effective than SLT.
- b. PGAs are easier to get approved by insurance companies.
- c. Patients are fearful of surgery and more comfortable with pharmacotherapy.
- d. Patient compliance is better with PGAs than SLT.
4. The primary effect of nitric oxide is?*
- a. Smooth muscle relaxation in the trabeculum
- b. Uveo-scleral pathway enhancement
- c. Decreased aqueous production
- d. Endothelial cell activation
5. Which molecule below is described as having a dual mechanism of outflow?*
- a. Netarsudil
- b. Latanoprost
- c. Latanoprostene bunod
- d. Travoprost
- e. Timolol maleate
6. Which mechanism of action best describes latanoprostene bunod?*
- a. Inhibition of carbonic anhydrase
- b. Reduction of episcleral venous pressure
- c. Increased uveoscleral outflow and increased trabecular outflow
- d. Rho kinase inhibition
7. Which mechanism of action best describes netarsudil?*
- a. Inhibition of carbonic anhydrase
- b. Reduction of episcleral venous pressure
- c. Increased uveoscleral outflow and increased trabecular outflow
- d. Rho kinase inhibition
8. What is the unique pharmacokinetic effect of Latanoprostene Bunod?*
- a. Alpha agonist
- b. Carbonic Anhydrase inhibition
- c. Neuro protection
- d. Nitric Oxide donation
9. Latanoprostene Bunod demonstrated what additional IOP lowering compared to latanoprost acid?*
- a. No additional effect
- b. 1.23 mmHg
- c. 3.81 mmHg
- d. 9.00 mmHg
10. Which molecule is best described as lowering IOP through the traditional/physiologic outflow pathway?*
- a. Netarsudil
- b. Latanoprost
- c. Brimonidine
- d. Travoprost
- e. Timolol maleate
11. A recently published meta-analysis found that ______________ and topical medication demonstrated similar success rates in IOP reduction for patients with open-angle glaucoma.*
- a. Microincisional glaucoma surgery
- b. Argon laser trabeculoplasty
- c. SLT
- d. Incisional surgery
12. __________ is considered a valuable marker by the panelists for predicting patient response to PGAs.*
- a. Baseline IOP
- b. Corneal hysteresis
- c. Presence of dry eye disease
- d. Patient age

Video Resources

Instructions

Step 1 of 3

33%

Profession:*
- MD/DO
- NP
- Nurse/APN
- PA
- OD
- Other
Years in Practice:*
- >20
- 11-20
- 6-10
- 1-5
- <1
Patients Seen Per Week: with the disease targeted in this activity*
- 0
- 1-5
- 6-10
- 11-15
- 15-20
- 20+
Region:*
- Northeast
- Northwest
- Mid-West
- Southeast
- Southwest
Setting:*
- Solo Practice
- Community Hospital
- Government or VA
- Group Practice
- Other
- I do not actively practice
Models of Care:*
- Fee for Service
- ACO
- Patient-Centered Medical Home
- Capitation
- Bundled Payments
- Other

Did the program meet the following educational objectives?*

	Agree	Neutral	Disagree
Explain how novel therapeutics differ in their methods of action from other topical medications.
Evaluate the safety and efficacy of latanoprostene bunod for ocular hypertension and primary open-angle glaucoma.
Describe how a healthy eye manages intraocular pressure in contrast with an unhealthy eye.

	Yes	No
The design of the program was effective for the content conveyed
The content supported the identified learning objectives
The content was free of commercial bias
The content was relative to your practice
The faculty was effective
You were satisfied overall with the activity
Would you recommend this program to your colleagues

Specialty

Course Type

Specialty

Course Type

Search

Menu

Specialty

Course Type

Search

Menu

Case Studies: Advances in Glaucoma Therapy

Webinar Credits: 1

Expiration Date: Tuesday, December 31, 2019

Release Date: December 2018
EXPIRATION DATES:
AMA PRA CATEGORY 1 CREDIT EXPIRATION DATE: DECEMBER 31, 2019
COPE EXPIRATION DATE: DECEMBER 10, 2021

Learning Objectives

Accreditation and Designation Statement

Faculty and Disclosures

Disclaimer

Pretest

Video Resources

Test

Instructions

Step 1 of 3

Case Studies: Advances in Glaucoma Therapy

Webinar Credits: 1

Expiration Date: Tuesday, December 31, 2019

Release Date: December 2018 EXPIRATION DATES: AMA PRA CATEGORY 1 CREDIT EXPIRATION DATE: DECEMBER 31, 2019 COPE EXPIRATION DATE: DECEMBER 10, 2021

Learning Objectives

Accreditation and Designation Statement

Faculty and Disclosures

Disclaimer

Please log in to view this course

Pretest

Video Resources

Test

Instructions

Step 1 of 3

Release Date: December 2018
EXPIRATION DATES:
AMA PRA CATEGORY 1 CREDIT EXPIRATION DATE: DECEMBER 31, 2019
COPE EXPIRATION DATE: DECEMBER 10, 2021